Your session is about to expire
← Back to Search
Other
RG7774 for Diabetic Retinopathy (CANBERRA Trial)
Phase 2
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial is testing a pill called RG7774 to see if it can help people with a specific stage of diabetic eye disease who still have good vision. The goal is to find out if the pill can improve or stabilize their eye condition.
Eligible Conditions
- Diabetic Retinopathy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Group CExperimental Treatment1 Intervention
Participants will receive a high oral dose of RG7774 QD
Group II: Group BExperimental Treatment1 Intervention
Participants will receive a low oral dose of RG7774 QD
Group III: Group APlacebo Group1 Intervention
Participants will receive an oral dose of placebo matched to RG7774 once daily (QD)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RG7774
2020
Completed Phase 2
~110
Find a Location
Who is running the clinical trial?
Hoffmann-La RocheLead Sponsor
2,444 Previous Clinical Trials
1,093,018 Total Patients Enrolled
1 Trials studying Diabetic Retinopathy
174 Patients Enrolled for Diabetic Retinopathy
Clinical TrialsStudy DirectorHoffmann-La Roche
2,212 Previous Clinical Trials
892,312 Total Patients Enrolled
1 Trials studying Diabetic Retinopathy
174 Patients Enrolled for Diabetic Retinopathy
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger